#1INVEST INDIA NATIONAL INVESTMENT PROMOTION & FACILITATION AGENCY INVEST INDIA EXCLUSIVE INVESTMENT FORUM PRESENTATION BY TELANGANA#2Telangana - Overview Ranked #1 among Life Sciences Hotspots in India Cerestra & KPMG Report USD 1.36 BN investments in Lifesciences in just last 4 years $ mim 40% share of Domestic Pharmaceutical Production 1/3rd of global vaccine production 20% of the USFDA approved facilities in India (200+) World's Largest Pharma Park - Hyderabad Pharma city India's largest-Medical Devices park India's first & largest R&D and Biotech cluster- Genome Valley Hyderabad, State Capital - Fifth Largest City in India, is most 'Livable City' for the 5th consecutive year. Large skilled workforce - 70% are youth TS-iPass - All approvals & Licences in 15-30 days Amazon received clearance in 10 days Micromax plant set up in 6 months#3Cluster based approach for Lifesciences sector . Genome Valley India's first and largest Life Sciences manufacturing cluster 4 out of 5 leading manufacturers of vaccine are present here and home to more than 200 companies • India's 1st National Resource Facility for Biomedical Research (NARF) Asia's leading R&D and Innovation Hotspot ว Hyderabad Pharma City World's largest integrated pharma cluster Regulatory enclave and Export promotion cell proposed as a part of the pharma city Environmentally cleared cluster with investment potential of $ 9.7 Bn • Боро • Medical Devices Park India's largest medical devices park Spread across 276 acres with dedicated ecosystem for MedTech innovation Asia's largest coronary stent manufacturing facility#4Sector Specific Industrial Parks - Overview • Hyderabad Pharma City 19000 Acres - World's largest integrated pharma cluster Recognized as National Investment and Manufacturing Zone (NIMZ) by Government of India All permits/ clearances already in place - no clearance required at unit level Utility Infrastructure- Roads, Water, Power, Steam, Chilled Water and IT network/ Digital platforms logistics and Cold chains Access to Specialized Warehouses, Provide integrated Cluster Benefits through economies of scale Phase I ready for allotment for companies to move in Medical Devices Park 276 Acres - India's largest medical devices park Asia's largest minimally invasive coronary stent manufacturing facility being set up at Medical Devices Park Launched in June 2017 - Within a short span on about 3 years, over 25 companies setting up R&D and Manufacturing units Strategically Located (50 Mins from Airport; 30 Mins from Financial District) Availability of world class facilities: Warehouse, Testing & Certification labs, Rapid Prototyping & Tooling Lab and many more Medtronic investing USD 162 Million in scaling up and expanding the current R&D centre into a state-of-the-art innovation centre#5Major Players gsk GlaxoSmithKline NOVARTIS SHANTHA A SANOFI COMPANY AUROBINDO Committed to Healthier Life amri Complex Science. Expert Solutions. Dr.Reddy's FERRING PHARMACEUTICALS BE Biological E. Limited Celebrating Life Everyday Medtronic Lonza INDIAN IMMUNOLOGICALS LTD. NEKTAR HETERO HETERO LAURUS Labs Knowledge Innovation. Excellence QU POND Mylan Better Health for a Better World Telangana is home to around 800 companies with a combined value of USD 50 Million#6Robust Policy Incentives Incentives offered 15% investment subsidy on Fixed Capital Investment for Micro and Small enterprise 100% Skilling costs to be borne by the government Mega investors of greater than INR 200 Cr (USD 35MN) to get Incentives Special Policies/ 50-75% Reimbursement of State Goods & Services Tax for period of 7 years from commercial production 50% Subsidy on the expenses incurred for quality certification/ patent registration Preferential status in state procurement contracts 100% Reimbursementon stamp & transfer duty on industrial land purchase (2 25% Subsidy on specific cleaner production measures INR 1 per unit Power subsidy or a period of 5 years from commencement of commercial production Governance Mechanisms and Facilitations Single Window Clearance: An effective clearance system for industries called Telangana State Industrial Project Approval and Self Certification System (TS- iPASS), under which Industrial projects >1 billion investment to be approved within 15 days All other projects within 30 days Telangana Lifesciences Industrial Infrastructure fund : To create high-quality turnkey factories, R&D laboratories, incubation centres and warehousing parks as a plug-n-play leasable infrastructure of international benchmark to the Lifesciences companies investing in the state Telangana Lifesciences Innovation fund: A dedicated vehicle to provide venture stage capital to promising firms undertaking Intellectual Property driven R&D in the lifesciences sector Commitment and Flexibility to meet or beat the best incentive offer offered by any State in the Country#7Success Story - Dr. Reddy's Laboratories Dr. Reddy's About The Speaker • Mr. Satish Reddy Chairman, Dr. Reddy's Laboratories & President, Indian Pharmaceutical Alliance Mr. Reddy joined Dr. Reddy's in 1993, and currently serves as the company's Chairman He is an active member of leading industry associations and has played a key role in shaping policies impacting the pharma industry such as drug pricing, patent laws & amendments to the drugs & cosmetics act About Dr. Reddy's Dr. Reddy's is an integrated pharmaceutical company committed to the purpose of "Good Health Can't Wait" The company has operations in all major global markets (US, EU, India, Russia, China & other emerging markets), and is present in APIs, generics, differentiated formulations, biosimilars & custom pharma services The company's revenues for FY20 stood at INR 17,460 Cr, with EBITDA of 4,643 Cr Founded in year 1984 in Hyderabad, Telangana Established with initial capital outlay of INR 25 lakh, it has gone on to become a leading global pharma company Chief growth drivers: strong leadership, favourable policy landscape, life Sciences ecosystem in Hyderabad, support from the Government of Telangana Future plans: Accelerating our transformation by focusing on three strategic themes - leadership in spaces, operational excellence & patient centric innovation